Short answer
CME Group (CME) filed an 8-K current report with the SEC on October 21, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.19 (Exhibit EX-99.19). Q3 2026 results for quarter ended September 30, 2026, released October 21, 2026.
CME Group 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results for quarter ended September 30, 2026, released October 21, 2026
- Exhibit 99.1 contains CME’s financial results and investor-relevant operating performance details
- Non-GAAP revenue, expenses, operating income, net income and EPS supplement GAAP results
- Non-GAAP reconciliation enables comparison with prior financial reports, though adjustments may include recurring items
Item EX-99.19 · Exhibit EX-99.19
- Q3 2026 revenue reached a record $1.7B, up from $1.5B, with net income rising to $1.0B
- Adjusted diluted EPS $3.02 versus $2.68, highlighting earnings growth beyond reported GAAP results
- Record ADV of 29.4M contracts, with double-digit growth across all six asset classes, supporting transaction-fee momentum
- Market data revenue rose 20% to a record $243M, strengthening recurring revenue diversification
- Nearly $1B returned to shareholders: $465M dividends and $524M repurchases
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CME Group 8-K filings
Get the next CME 8-K as it lands
Follow CME for push alerts, or ask the research agent what this filing means.